Amazon.com Inc. (AMZN) Buys Ivona, Gets New Price Target

Page 1 of 2

Amazon.com Inc. (NASDAQ:AMZN) has been producing some headlines over the last month or so, and that seems to generate some excitement and enthusiasm around the company’s quarterly earnings report, which is due Wednesday of this week. One analyst has upgraded its outlook and raise its price target, and Amazon made some more news recently by buying a Europe-based txt-to-speech technology company – which may suggest the genesis of new products that could challenge some tech rivals.

First, a recent article looked a little deeper into the recent acquisition of Poland-based Ivona Software by Amazon.com Inc. (NASDAQ:AMZN).┬áIvona is a text-to-speech specialist firm that develops the technology for significant numbers of businesses, customers and developers. While there is no official word of how much Amazon spent for the purchase – light may be shed on this Wednesday during the earnings call – this purchase may fan more rumors that have swirled about the online retailer moving into more direct competition with Apple Inc. (NASDAQ:AAPL), Google Inc. (NASDAQ:GOOG) and Microsoft Corporation (NASDAQ:MSFT) by producing its own smartphone. At the very least, though, this might be a step toward improving the audio e-books for Kindle owners. But that would seem to innocuous for the company to put forth so much money to buy a company, when Amazon may be perfectly capable of developing and improving its own capability.

Amazon.com, Inc. (NASDAQ:AMZN)Would Amazon.com Inc. (NASDAQ:AMZN) develop a rival to Siri by Apple Inc. (NASDAQ:AAPL) or S-voice by Samsung? Ivona Software has indicated that it plans to increase its voice library to 50 in 17 languages this year.

While there is no indication that the purchase of Ivona has any impact, Piper Jaffray posted a research note Monday that reiterated the company’s Overweight rating, but raised its price target on the stock from $297 to $329 per share.

As of 1 p.m. ET Monday, Amazon.com Inc. (NASDAQ:AMZN) was down about 2.5 percent on the day to about $276.50 per share. What did Piper Jaffray have to say in its research note that generated such a change in its price target?

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!